[PDF] Top 20 Methylation status of DDIT3 gene in Chronic Myeloid Leukemia
Has 10000 "Methylation status of DDIT3 gene in Chronic Myeloid Leukemia" found on our website. Below are the top 20 most common "Methylation status of DDIT3 gene in Chronic Myeloid Leukemia".
Methylation status of DDIT3 gene in Chronic Myeloid Leukemia
... of DDIT3 in the regulation of cellular growth and differentiation ...of DDIT3 transcript has been found to induce increased apoptosis of myeloid cells and block cells in the progres- sion from G1 to ... See full document
5
GPX3 promoter methylation in chronic myeloid leukemia (CML) remains unknown. Our
... promoter methylation in chronic myeloid leukemia (CML) remains ...the methylation status of GPX3 promoter and its clinical relevance in ...quantitative ... See full document
8
Study of Akt1 Gene Intronic Variant in Chronic Myeloid Leukemia
... study was conducted on 50 CML and 50 normal healthy controls for which all the essential data on variables was recorded. Case- control study did not reveal any significant association of the variant allele with the ... See full document
37
Oxidative Stress and Antioxidant Status in Acute and Chronic Myeloid Leukemia Patients
... The substances that can damage DNA and cause cancer are known as free radical (FR) producers. Free radicals induce changes in the sequence of DNA viz. deletions, gene amplification, rearrangement and mutations, ... See full document
6
Aberrant Methylation of APAF-1 Gene in Acute Myeloid Leukemia Patients
... the methylation pattern in APAF-1 promoter region, as well as the expression of APAF-1 in AML ...of methylation status of APAF-1 gene promoter in patients with AML showed that APAF-1 ... See full document
7
Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia
... maintain methylation status of hematopoietic stem and progenitor cells [51, ...DNA methylation regulator, was thought to have a severe im- pact on DNA methylation patterns [53, ...in ... See full document
10
<p>Myeloid Blast Crisis of Chronic Myeloid Leukemia Followed by Lineage Switch to B-Lymphoblastic Leukemia: A Case Report</p>
... Chronic myeloid leukemia (CML) is a common myeloproliferative disease char- acterized by the BCR-ABL fusion gene from the chromosomal translocation t(9; 22)(q34;q11), which is referred to as ... See full document
6
KIR repertory in patients with hematopoietic diseases and healthy family members
... lymphoblastic leukemia; AML: Acute myeloid leukemia; BMT: Bone marrow transplantation; CML: Chronic myeloid leucemia; DNTPs: Deoxynucleotide; EDTA: Ethylene tetraacetic acid; EFS: ... See full document
10
High imatinib dose overcomes insu cient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients
... 19. Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid ... See full document
10
MicroRNA-binding site polymorphisms in hematological malignancies
... was evaluated in 137 patients with multiple myeloma who underwent autologous stem cell transplantation [13]. Asso- ciation with survival was observed for two SNPs: CC geno- type of rs3660 in KRT81 conferred longer ... See full document
6
Karyotyping in Chronic Myeloid Leukemia
... in c-abl gene in exon a2 can skip splice donor sites in c-abl exons a1 and b1 to fuse with splice donor sites of the juxtaposed bcr. Two potential junctions are encoded depending on whether bcr exon 2 (b2) or bcr ... See full document
136
Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report
... Patient’s inclusion criteria: A CML patient with oral dose of 400 mg/day for nine months of Gleevec who has no hematological, cytogenetic and molecular response to drug was investigated for ABL gene ATP-binding ... See full document
5
Systematic analysis of somatic mutations driving cancer: uncovering functional protein regions in disease development
... cancer gene list is a very strong indication of being a true cancer ...cancer gene datasets as they are absent from all four studied ...this gene and the development of gastric and colorectal cancers ... See full document
23
IGF-IR determines the fates of BCR/ABL leukemia
... Chronic myeloid leukemia (CML) is a hematopoietic malig- nancy that results from the t(9;22)(q34;q11) Philadelphia (Ph) chromosome translocation, which produces the BCR/ ABL fusion oncogene ...the ... See full document
9
Quality control, modeling, and visualization of CRISPR screens with MAGeCK VISPR
... quality control (QC), data analysis, and visualization method for CRISPR screen was not available. Several algo- rithms are developed for screening analysis on microarray or high-throughput sequencing data, such as RIGER ... See full document
13
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies
... DNA methylation is still unknown ...SRSF2 gene mutation may be associated with a low Alu methyla- tion profile requires to be confirmed by increasing the number of ...in methylation pathways ... See full document
11
SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
... An independent prognostic scoring system for CMML, CPSS-Mol, was developed by incorporating clinical fea- tures and status of 38 commonly mutated genes in CMML [45]. The learning cohort consisted of 214 CMML ... See full document
5
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
... positive POC achieved regulatory approval, as opposed to 15-30% of those that had no putative biomarker or for which POC studies were not performed or had negative results [6]. For this very reason, regulatory agencies, ... See full document
10
Case Report Fourth malignancy after treatment of Hodgkin’s lymphoma: a case report
... Abstract: Objective: To evaluate the incidence and treatment of the fourth malignancy in a Hodgkin’s lymphoma (HL) patient. Methods: We reported a HL patient after treatment that developed the second, third, and fourth ... See full document
5
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
... Aberrant spliceosome function secondary to mutated SRSF2 has been associated with mis-splicing of multiple genes (e.g. EZH2, RUNX1, BCOR, IKAROS and CASP8, etc.) that are implicated in pathogenesis of myeloid neo- ... See full document
7
Related subjects